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Abstract
Despite having pathological changes in the brain associated with Alzheimer’s disease (AD), some patients have preserved
cognitive function. A recent epidemiological study has shown that diet, exercise, cognitive training, and vascular risk monitoring interventions may reduce cognitive decline in at-risk elderly people in the general population. However, the details of
molecular mechanisms underlying this cognitive function preservation are still unknown. Previous reports have demonstrated
that enriched environments prevent the impairment of hippocampal long-term potentiation (LTP) through b2-adrenergic
signals, when LTP is incompletely suppressed by synthetic amyloid-b (Ab) oligomers. The cholinergic network from the medial
septal nucleus (MSN) is also a main modulating system for hippocampal glutamatergic neural activation through nicotinergic
and/or muscarinergic acetylcholine receptors. Previously, we reported the importance of a cholinergic regulator gene in the
MSN, hippocampal cholinergic neurostimulating peptide (HCNP). By using hippocampal sections from mice, we here
demonstrated that the cholinergic neural activation from the MSN enhanced the glutamatergic neuronal activity during
unsaturated LTP but not during saturated LTP. Synthetic Ab oligomers suppressed the hippocampal glutamatergic activity in a
concentration-dependent manner. Furthermore, HCNP, as well as a cholinergic agonist acting through the muscarinic
M1 receptor, prevented the suppression of hippocampal glutamatergic neuronal activity induced by synthetic Ab oligomers.
This result suggests that the persisting cholinergic activation might be a potential explanation for the individual differences in
cognitive effects of AD pathological changes.
Keywords
hippocampal cholinergic neurostimulating peptide (HCNP), cholinergic modulation, muscarinic receptor, long-term
potentiation (LTP), Ab oligomers, phosphatidylethanolamine-binding protein (PEBP)

Introduction
Senile plaques, neurofibrillary tangles, and neuronal cell
death are the neuropathological hallmarks of Alzheimer’s
disease (AD).1 Amyloid-b (Ab) is the main pathogenic feature of AD and forms the basis for the amyloid hypothesis of
AD.2 However, several therapeutic interventions reducing
Ab have failed to ameliorate the loss of cognitive function
in patients with AD. Conversely, there is evidence that some
people can tolerate more AD-related pathological changes
than others, having “cognitive reserve.”3,4 In individuals
with cognitive reserve, the functional network connection
in the cerebral cortex can be visualized as intact using functional magnetic resonance imaging (fMRI).5 Interestingly,
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recent studies have suggested that a nutritious diet, physical
activity, social engagement, and mental stimulation inhibit
cognitive decline in aged individuals.6-10 An intervention
study of diet, exercise, cognitive training, and vascular risk
monitoring also revealed a reduction in the decline of cognitive function in at-risk elderly people in the general
population.11 This epidemiological evidence indicates the
possibility of maintaining cognitive function even if
AD-related pathological changes, such as amyloid deposition and aggregation of tau protein, occur within the brain.
However, the details of the molecular mechanisms underlying the preservation of cognitive function in the presence of
AD-related pathological changes are still unknown.
Much AD research has focused on the septal cholinergic
neurons because they degenerate early in the disease progression. This observation is validated by the clinical usefulness of cholinesterase inhibitors. Hippocampal function is
dynamically regulated by postsynaptic transmission in the
mono- and tri-glutamatergic pathways from the dentate
nucleus to CA1 area. The cholinergic neural formation from
the medial septal nuclei (MSNs) to the hippocampus regulates the hippocampal glutamatergic neural activity.12 Cholinergic dysfunction is involved in memory disturbances in
AD and schizophrenia.13 This suggests that the septohippocampal cholinergic network may be of crucial importance for the regulation and maintenance of glutamatergic
neural activity in the hippocampus.
Hippocampal cholinergic neurostimulating peptide
(HCNP), originally purified from juvenile rat hippocampus,
was first reported as an acetylcholine synthesis regulating
peptide in the MSN by Ojika et al. in 1992.14,15 HCNP
induces acetylcholine synthesis by increasing the amount
of choline acetyltransferase in the MSN. This peptide is
formed at the N-terminal region of the 21-kD HCNP precursor protein (HCNP-pp), which is composed of 186 amino
acids. We have also reported that overexpression of HCNPpp in the hippocampus may enhance the glutamatergic
neuronal activity, measured by the slope of field excitatory
postsynaptic potentials (fEPSPs) during long-term potentiation (LTP), via the muscarinic M1 receptor, indicating that it
is a factor regulating the hippocampal glutamatergic neurons.16 A previous report also demonstrated that synthetic
amyloid oligomers generated by mutant Ab 1 to 40 peptides
(AbS26C, serine to cysteine at amino acid 26) could inhibit
glutamatergic neuronal activity in a concentrationdependent manner.17
In this study, we investigated whether overexpression of
HCNP can enhance LTP in the hippocampus when synthetic amyloid oligomers inhibit glutamatergic neural
activation. We report that cholinergic neural activity
enhances glutamatergic neuronal activity, as measured
by the fEPSP slope in unsaturated, but not saturated, LTP.
Furthermore, overexpression of HCNP (HCNP-pp), as well
as the cholinergic agonist, carbachol (CCh), rescued the
glutamatergic neural activity from reduction by synthetic
amyloid oligomers.
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Materials and Methods
Animals
Male 6- to 8-wk-old C57BL/6J mice were used in
experiment 1. And 12- to 15-wk-old HCNP-pp heterozygous transgenic (HCNP-pp Tg) mice, driven by a Ca2þ
CaMKII promoter, and their wild-type (WT) littermates
were used in experiment 2. All animals were kept under
pathogen-free conditions on a 12 h light/dark schedule
(light on 07:00 to 19:00) and given free access to food and
water. These experiments were approved by the Animal
Care and Use Committee of Nagoya City University
Graduate School of Medical Sciences and conformed to
guidelines for the use of laboratory animal published by
the Japanese government (Law No. 105, October 1973).

Slice Preparation
Mice were deeply anesthetized with halothane and decapitated. The brains were quickly removed and transverse hippocampal slices with a 400-mm thickness were prepared
using a vibrating slice cutter (Linear Slicer Pro 7, Dosaka,
Kyoto, Japan) in ice-cold solution containing (millimole:
mM) sucrose, 260; KCl, 3; NaH2PO4, 1.25; NaHCO3, 26;
D-glucose, 10; MgCl2, 1 (pH 7.4), which was continuously
bubbled with 95% O2/5% CO2. One to 4 slices were obtained
from each animal and 1 experiment was performed on each
slice. The hippocampal slices were incubated for 30 min in
artificial cerebrospinal fluid (ACSF) containing (mM) NaCl,
125; KCl, 2.5; CaCl 2, 2.4; MgCl 2 , 1; NaH 2PO 4 , 1.25;
NaHCO3, 25; D-glucose, 12.5; saturated with 95% O2/5%
CO2 (pH adjusted to 7.4) at 32  C. Slices were kept at room
temperature (25 + 1  C) in ACSF at least for 1 h until ready
for recording.

Electrophysiology
The slices were fixed in a recording chamber (*0.4-mL
volume, RC-26GLP, Warner Instruments, Hamden, CT,
USA) under a nylon mesh attached to a stainless steel
anchor, then submerged in, and continuously perfused with,
ACSF at a flow rate of 2 mL/min. All experiments were
performed at room temperature (25 + 1  C). The fEPSPs
were recorded from the stratum radiatum (SR) in the CA1
field using borosilicate glass electrodes (3 to 5 MΩ) filled
with perfusing ACSF. Recordings were made using an Axopatch 200B amplifier (Axon Instruments, Foster City, CA,
USA) with a high-cut filter at 2 kHz.
A stainless steel concentric bipolar electrode (Unique
Medical, Tokyo, Japan) was placed on the SR, and the Schaffer collateral–commissural fibers (SCs) were stimulated with
a 0.1-ms pulse every 30 s. At the beginning of each experiment, a stimulus–response curve was established, and the
stimulus intensity was adjusted to evoke 30% to 50% of the
maximal response, which fell within the stimulus intensities
of 20 to 40 mA. LTP in the CA1 region was induced by
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single, double, or triple tetanic stimulation (TS; 0.1-ms pulse
duration, 100 Hz for 1 s) to the SCs. The fEPSPs were
recorded in CA1 for 60 min after the LTP induction.

Neuronal Projection of Cholinergic Efferent Terminals
from MSN by Neuron Tracing
To visualize the efferent cholinergic neurons from MSN, a
total of 500 nL of recombinant adeno-associated virus
including green fluorescent protein (GFP) driven by syn
promoter (rAAV2/1-Syn-GFP; 1.18  10 13 vector
genomes/mL, Addgene, MA, USA) solution was injected
by a glass pipette (tip diameter 25 to 30 mm) connected to
a picospritzer into MSN, then the pipette was maintained in
place for an additional 10 min. Mice were sacrificed 2 to
3 wk after the injection and fixed to prepare the coronal
slices for microscopy, and a total of 3 mice were used.

Synthesis of Ab Oligomer Proto-Fibrils and Thioflavin T
(ThT) Assay
AbS26C (DAEFRHDSGYEVHHQKLVFFAEDVGCNKGAIIGLMVGGVV) was purchased from Medical & Biological Laboratories (MBL) Co., Ltd. (Nagoya, Japan).
Following a previous report, we generated Ab oligomer
proto-fibrils.17 In brief, AbS26C peptides were solubilized
at 0.18 mg/mL in MilliQ water, diluted 1:1 with 20-mM
ammonium bicarbonate (pH 8.2) to a 20-mM (with respect
to monomer) peptide solution. These were incubated at room
temperature for 5 d and bubbled with oxygen for 5 to 10 min
each day. AbS26C peptides form dimers by disulfide crosslinking. After lyophilization, monomeric and dimeric mutant
Ab peptides were subsequently assembled into higher
ordered oligomer proto-fibril-like aggregates by incubation
at 37  C for 5 d in 20 mM phosphate buffer (pH 7.4).
AbS26C assembly was investigated using a 2 mM ThT
(Sigma-Aldrich, St. Louis, MO, USA) binding assay, indicating b-sheet conformation. After shaking for 15 s, each
100 mL reaction sample with 15 mL of 2 mM ThT solution
was monitored in real time by ThT fluorescence (Ex 440 nM
and Em 480 nM). The fluorescence of each sample was
assessed by the averaging of triplet reactions. In electron
microscopy (EM), the conformation of oligomer protofibril-like aggregates was confirmed. Negative contrast
EM was performed as described in a previous report.18 In
brief, samples were applied to carbon-coated grids and
observed using EM (JEM-1011J, Nihondenshi, Tokyo,
Japan) after staining with 2% (w/v) uranyl acetate solution
(Merck, Darmstadt, Germany).

Application of Drug and Synthetic AbS26C Oligomer
for In Vitro Electrophysiology
CCh (50 nM; a cholinergic agonist) and pirenzepine
(0.1 mM; a selective muscarinic M1 receptor antagonist)
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
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These drugs were dissolved in ACSF and applied by gravity
feed from 60 mL reservoirs bubbled with 95% O2/5% CO2,
from 15 min before LTP induction to 5 min after LTP induction. In the electrophysiological experiments to assess the
suppressive effect of synthetic AbS26C oligomer, 50 nM,
75 nM, or 100 nM AbS26C (with respect to monomers) in
ACSF was continuously applied from 20 min before the
induction of LTP until the end of recording. To assess cholinergic effects, fresh hippocampal slices were treated with
50 nM CCh solution containing synthetic AbS26C oligomer
for 20 min before LTP induction.

Data Acquisition and Statistical Analysis
All data were included in the final analyses except when the
baseline response changed during the experiment. The
fEPSPs were sampled online at 4 kHz (PowerLab AD Instruments, Sydney, Australia), stored on hard disk, and analyzed
off-line with Scope 4 and Chart 5 (AD Instruments). The
maximal slope values of the initial rising phase of fEPSPs
were measured to avoid contamination of voltage-dependent
components as much as possible. The magnitude of LTP was
calculated as a percentage of the averaged fEPSP slope values from 50 to 60 min after each TS relative to the baseline
fEPSP slope values. Derived parameters were expressed as
the mean + standard error of mean (SEM) (n ¼ number of
slices, N ¼ number of animals) and compared using one-way
analysis of variance (ANOVA) followed by multiple comparisons (Bonferroni corrected multiple t test) or unpaired t
test with the level of significance set at P < 0.05.

Results
Experiment 1: Contribution of Cholinergic Mechanisms
to Enhancement of LTP in CA1
Variations in LTP determined by the number of preconditioning
tetanic stimuli. We previously reported that cholinergic neuronal stimulation could enhance the fEPSP slopes in hippocampal LTP, via muscarinic M1 receptor, with single TS as
preconditioning.16 In past reports, the different natures of the
preconditioning stimuli, that is, tetanus or theta burst, have
been shown to influence LTP enhancement through different
types of glutamate receptors. 19 Our first question was
whether the degree of preconditioning by TS could influence
the induction of LTP. To examine the effect of glutamatergic
activity on activity-dependent plasticity in pyramidal neurons, LTP in the SR of the CA1 region was investigated.
After recording stable fEPSPs in the CA1 region, TS
(100 Hz for 1 s) was applied to the SCs. To change the grade
of glutamatergic activity inducing LTP, we used preconditioning single, double, or triple TS on SCs. At 50 to 60 min
after single TS, fEPSP slopes increased to 118.6% + 1.9%
(n ¼ 5, N ¼ 3) of the baseline, indicating LTP induction
(Fig. 1). In comparison with the fEPSP slope after single TS,
those after double or triple TS were markedly enhanced to
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Fig. 1. The effect of the number of preconditioning tetanic stimulations on long-term potentiation (LTP) amplitude. Time courses of
field excitatory postsynaptic potentials (fEPSPs) are shown in (A).
Tetanic stimulation (TS; 0.1 ms, 100 Hz for 1 s) was applied to the
Shaffer collateral-commissural fibers (SCs) at time 0 with the repetitions indicated (filled circles; S-TS; single TS, n¼5, open circles;
D-TS; double TS n-11, filled triangles; T-TS; triple TS n¼7). Representative traces of fEPSP were taken from 0 to 10 min before TS
(gray line) or 50 to 60 min after TS (black line). When measured at
50 to 60 min after TS, LTP induced by D-TS or T-TS was significantly enhanced in comparison with that induced by S-TS (A,B).
However, LTP induced by T-TS was not enhanced beyond that
of D-TS. Data are expressed as the mean + SEM. *P < 0.05.
**P < 0.01.
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Fig. 2. Cholinergic modulation of LTP induced by S-TS. Prior application of 50 nM carbachol (horizontal bar) significantly enhances
fEPSP slope in LTP induced by S-TS (A). Simultaneous administration of pirenzepine (Prz, 0.1 mM), a M1 receptor antagonist, blocks
the enhancement by carbachol, indicating muscarinic modulation of
LTP enhancement in this condition (filled circles; control n ¼ 5,
filled triangles; carbachol [CCh] 50 nM n ¼ 7, open circles; CCh 50
nM þ Prz 0.1 mM n ¼ 5). Bar graphs show the percentage change in
LTP at 50 to 60 min after S-TS (B). Data are expressed as the mean
+ SEM. *P < 0.05.

150.6% + 4.9% (n ¼ 11, N ¼ 5; P < 0.01) or 142.2% +
1.8% (n ¼ 7, N ¼ 3; P < 0.05), respectively (Fig. 1). Triple
TS did not enhance fEPSP slopes beyond that achieved with
double TS. These results suggest that the strength of LTP
depends on the degree of glutamatergic activity preconditioning and is saturated at a fixed level.
The effect of cholinergic modulation on different degrees of LTP.
Numerous reports have demonstrated that cholinergic stimulation may modulate glutamatergic activity-dependent plasticity via nicotinergic and/or muscarinergic receptors in LTP
and its converse, long-term depression.20-22 Our next question was whether the cholinergic modulating system plays an
important role in the enhancement of LTP resulting from
single and double TS. To examine the difference in cholinergic modulation depending on the degree of glutamatergic
preconditioning on LTP, we investigated the cholinergic
modulating effect by continuous application of CCh
(50 nM) from 15 min before LTP induction by single TS
to 5 min after LTP induction. The application of CCh
enhanced the fEPSP slope (136.0% + 4.5%, n ¼ 7,
N ¼ 5) when compared with control (118.6% + 1.9%,
n ¼ 5, N ¼ 3) following single TS (P < 0.05; Fig. 2). This
enhancement was extinguished by pirenzepine (0.1 mM;
122.9% + 5.2%, n ¼ 5, N ¼ 3), suggesting this modulating
effect on LTP via muscarinic M1 receptors. In contrast, the
enhancement of fEPSP slope by CCh was not observed
under double TS LTP induction (140.0% + 10.5%,
n ¼ 11, N ¼ 5) compared to that without CCh (150.6% +
4.9%, n ¼ 11, N ¼ 5; Fig. 3).

Fig. 3. No modulating effect of cholinergic activity on LTP induced
by D-TS. No significant enhancement of fEPSP slope was seen with
prior application of CCh, (50 nM; horizontal bar), in D-TS-induced
LTP. Pirenzepine (Prz, 0.1 mM) depressed LTP to a level similar to
the control induced by single tetanic stimulation (S-TS; filled circles;
control n ¼ 11, open circles; CCh 50 nM n ¼ 11, open triangles; Prz
0.1 mM n ¼ 10; A). Bar graphs show the percentage change in LTP at
50 to 60 min after D-TS (B). Data are expressed as the mean +
SEM. *P < 0.01.

Next, to examine the involvement of cholinergic activity in
the enhancement of fEPSP slope from single and double TS,
we applied pirenzepine (0.1 mM) before LTP induction by
double TS. The fEPSP slope was significantly reduced to a
level similar to that resulting from single TS (122.1% +
3.0%, n ¼ 10, N ¼ 4; P < 0.05; Fig. 3). However, the application of atropine, a nonspecific muscarinic antagonist, did
not reduce the fEPSP slope induced by single TS (data not
shown, see Ref.16). These data suggest that cholinergic activation via muscarinic M1 receptors play a crucial role in the
enhancement of fEPSP from single to double TS, and LTP
induced by double TS represents the maximum postsynaptic glutamatergic activity possible. This may involve
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Fig. 4. Cholinergic projections from the medial septal nucleus (MSN) to the stratum radiatum (SR). Neuronal tracing by injection of
recombinant adeno-associated virus into the MSN reveals the innervation to the SR (A). Efferent terminals from the MSN may project to
postsynapses in the SR of CA1(b)–CA3(a), where the recording and stimulating electrodes, respectively, were placed as shown in schematic
diagram (B).

full translocation of a-amino-3-hyrdoxy-5-methyl-4isoxazolepropionic acid (AMPA) receptors within the postsynaptic button and cholinergic neuronal activity through
muscarinic M1 receptor leading to the enhancement of fEPSP
slopes in double TS, but not in LTP induced by single TS.
Neuronal projection of cholinergic efferent terminals from the
MSN to the SR. Our next question was whether cholinergic
efferent terminals project from the MSN to the SR of
CA3–CA1 and the SCs. We stimulated preglutamatergic
neurons on the SCs and recorded fEPSPs in the SR of the
CA1 region. Previous reports have demonstrated that the
main region of cholinergic projection from MSN might be
the stratum oriens in CA1, the stratum oriens in CA3, and the
hilus of the dentate gyrus.21 To verify our finding of cholinergic activity in the enhancement of LTP by double TS, we
confirmed the existence of neuronal projections of cholinergic efferent terminals from the MSN in the SR of CA3–CA1
and SCs by a neuronal antegrade tracing method using
AAV-GFP-injected into the MSN. Efferent synaptic terminals were observed in the SR of CA3–CA1 as well as in both
the stratum oriens and the hilus of the dentate gyrus (Fig. 4).

Experiment 2: Protective Effect of Cholinergic
Modulations against the Synthetic Ab OligomerInduced Suppression of LTP in CA1
Suppressive effect of synthetic AbS26C oligomer on LTP. Our
data suggest that cholinergic activity can modulate and
enhance LTP in unsaturated postsynaptic glutamatergic
neurons. We next investigated whether cholinergic
activity could also modulate LTP when the postsynaptic
glutamatergic activity is suppressed by an exogenous factor,
such as synthetic AbS26C oligomer.

To morphologically confirm the alteration from dimeric
AbS26C to proto-fibrils, we observed the incubated AbS26C
using a transmission electron microscope (TEM). Negative
contrast EM showed that dimeric AbS26C changed to chainlike, proto-fibril-like structures 5 d after incubation and
remained stable (Fig. 5A). We also observed that these
proto-fibril-like structures were ThT positive, indicating that
they contain b-sheets, and the ThT-positive intensity gradually increased over 5 d (Fig. 5B). These results suggest that
dimeric AbS26C can change to proto-fibril-like structures
containing b-sheets, as seen in nonsynthetic Ab oligomers.17
We then confirmed the suppressive effect of synthetic
AbS26C oligomers on LTP in the hippocampus of WT mice
at 12 to 15 wk old. Synthetic AbS26C oligomers were perfused at a concentration of 50 nM, 75 nM, or 100 nM, calculated by the amount of AbS26C monomer. We evaluated
the inhibitory effect of synthetic AbS26C oligomers in LTP
induced by single TS. Twenty minutes after the application,
the induction and evaluation of LTP were started. The fEPSP
slope was suppressed by 100 nM synthetic Ab oligomers
(105.8% + 3.9%, n ¼ 6, N ¼ 4; P < 0.05 vs. control)
compared with control (122.7% + 2.4%, n ¼ 10, N ¼ 7).
Two lower concentrations of synthetic Ab oligomers had no
significant effect (50 nM: 117.8% + 4.2%, n ¼ 6, N ¼ 4, P >
0.05 vs. control, 75 nM: 110.6% + 8.6%, n ¼ 4, N ¼ 2, P >
0.05 vs. control; Fig. 5C and D). This suggests that synthetic
Ab oligomers can suppress the fEPSP slope enhanced by
single TS in a concentration-dependent manner.
Cholinergic rescue of the fEPSP slope suppression by synthetic
AbS26C oligomers. We next investigated whether cholinergic
stimulation could rescue fEPSP slopes from suppression
by 100 nM synthetic AbS26C oligomers. The effects of
co-application of 50 nM CCh and 100 nM synthetic AbS26C
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Fig. 5. Aggregated amyloid oligomers biologically suppress synaptic
activity in LTP. In negative contract transmission electron microscope (TEM), mutant amyloid monomer (AbS26C) morphologically
aggregates, in a time-dependent fashion, when incubated at 37  C.
Proto-fibril-like assemblies were observed after incubation for 5 d
(A). Thioflavin-T binding fluorescence analysis revealed a significant
increase in intensity after incubation for 5 d (P < 0.01), indicating
the presence of b-sheet rich structures (n ¼ 4 in each group; B). In
LTP induced by S-TS in wild-type mice, proto-fibril-like assemblies,
applied as indicated by the horizontal bar, significantly suppressed
fEPSP slope in a concentration-dependent manner, indicating synaptic toxicity on the glutamatergic neural network. Representative
traces of fEPSP were taken from 0 to 10 min before tetanic stimulation (TS; gray line) or 50 to 60 min after TS (black line; C). Percentage changes in LTP at 50 to 60 min after S-TS (D). Data are
expressed as the mean + SEM. *P < 0.05. NS, not significant.

oligomers to hippocampal slices 20 min before LTP induction were investigated (Fig. 6). The CCh-induced enhancement of fEPSP slope following single TS was not suppressed
by synthetic AbS26C oligomers (CCh: 127.0% + 6.0%,
n ¼ 5, N ¼ 4, CCh with AbS26C: 125.1% + 4.5%, n ¼ 4,
N ¼ 3). This suggests that the exogenous cholinergic stimulation can rescue glutamatergic neuronal activity from
functional suppression by synthetic AbS26C oligomers.
We had previously generated CaM Kinase II promoterdriven HCNP-pp transgenic (HCNP-pp Tg) mice. In these,
the amount of choline acetyltransferase in the MSN is specifically increased,23 and the fEPSP slopes of LTP induced
by single TS are enhanced via M1 muscarinic modulation in
the hippocampus at 12-wk-old.16 Our final question was
whether HCNP-pp could rescue fEPSP slopes in LTP
induced by single tetanus following suppression by 100
nM synthetic AbS26C oligomers. To investigate this, fEPSP
slopes were evaluated using hippocampal slices from
HCNP-pp Tg mice. No suppression of fEPSP slope by 100
nM synthetic AbS26C oligomers was seen in HCNP-pp Tg
mice (HCNP-pp Tg with Ab oligomers: 143.0% + 4.9%, n
¼ 7, N ¼ 4, HCNP-pp Tg alone: 140.1% + 7.0%, n ¼ 7, N ¼
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Fig. 6. Cholinergic activation through muscarinic receptors rescues glutamatergic activity in the presence of synthetic amyloid-b
(Ab) oligomers in wild-type mice. No significant change in prior
application of carbachol (dashed bar) was shown in long-term
potentiation (LTP) in the presence of synthetic Ab oligomers (horizontal bar) when compared with that without synthetic Ab oligomers. This suggests that carbachol rescues glutamatergic activity
influenced by synaptic toxicity by synthetic Ab oligomers (filled
triangles; 50 nM carbachol [CCh] þ 100 nM Ab n ¼ 4, open circles;
50 nM CCh þ buffer n ¼ 5; A, B). Representative traces of field
excitatory postsynaptic potential were taken from 0 to 10 min
before tetanic stimulation (TS; gray line) or 50 to 60 min after TS
(black line). Percentage changes in LTP at 50 to 60 min after TS.
Data are expressed as the mean + SEM (B). NS, not significant.

Fig. 7. Overexpression of hippocampal cholinergic neurostimulating peptide precursor protein (HCNP-pp) prevents long-term
potentiation (LTP) suppression by synthetic amyloid-b (Ab) oligomers. In LTP induced by single tetanic stimulation (S-TS) in HCNPpp Tg mice, application of synthetic Ab oligomers (horizontal bar)
had no significant effect on the field excitatory postsynaptic potential (fEPSP) amplitude, indicating a protective effect of hippocampal
cholinergic neurostimulating peptide (HCNP) against Ab synaptic
toxicity in glutamatergic neural activation (A, B). Representative
traces of fEPSP were taken from 0 to 10 min before tetanic stimulation (TS; gray line) or 50 to 60 min after TS (black line). Percentage
changes in LTP at 50 to 60 min after TS. Data are expressed as the
mean + SEM (B). NS, not significant.

4; Fig. 7). These data suggest that HCNP, as well as being a
cholinergic stimulant, can prevent fEPSP slope suppression
by synthetic AbS26C oligomers in hippocampal LTP.

Discussion
In this study, we demonstrated that (1) a single preconditioning TS induced unsaturated LTP, which showed a small
increase in the fEPSP slope. Double and triple TS caused a

1548

further enhancement of the fEPSP slope, but the magnitude
of the fEPSP slopes was similar between these stimuli, indicating saturation of LTP at this level of stimulation, (2) the
cholinergic neuronal activity through muscarinic M1 receptors produced the enhancement of fEPSP slope seen between
single and double TS; (3) synthetic Ab oligomers, such as
AbS26C, suppressed enhancement of fEPSP slope in unsaturated LTP induced by single TS in a concentrationdependent manner; (4) HCNP, as well as being a cholinergic
stimulant, prevented the suppression of fEPSP slope by
synthesized Ab oligomers in hippocampal LTP.
The induction of LTP by high-frequency TS is used to
assess the pharmacological mechanisms of synaptic
function.24 The magnitude of LTP is sensitive to several
experimental variables and differs between individual
experiments. Past reports have demonstrated that the type
of preconditioning stimulation, that is, the frequency or
intensity of stimulation, can induce different magnitudes of
LTP enhancement through different types of glutamate
receptors.25,26 High-frequency TS immediately exceeds the
LTP induction threshold. However, preconditioning lowfrequency stimulation can suppress the magnitude of LTP
subsequently induced by high-frequency stimulation,
through activation of inositol 1,4,5-triphosphate receptors.27
The magnitude of LTP typically also increases in parallel
with tetanus intensity, whereas strong tetanization, that is
high-intensity current, sometimes results in a paradoxical
depression of fEPSP slope.25 To indicate the enhancing
effect of HCNP on LTP, we used single high-frequency
TS as described in a previous report.16 In this experimental
condition, single high-frequency TS did not exceed the saturated fEPSP slope. In this study, to determine the effect of
the number of preconditioning TS needed to produce saturated LTP, we investigated single, double, and triple TS on
SCs as preconditioning factors. We found that LTP strength
depends on the degree of preconditioning glutamatergic
activity and is saturated by double high-frequency TS. However, the precise mechanism underlying this enhancement is
still not understood.
We also investigated the involvement of cholinergic activation, through muscarinic M1 receptors, in the difference in
enhancement between single and double TS. Cholinergic
neurons originated from MSN mainly project and innervate
both CA1 and CA3 SR in hippocampus, 28,29 where
recording and stimulating electrodes were placed in these
experiments, respectively. The modulating effect of cholinergic activity on hippocampal synaptic plasticity may be
concentration-dependent. A low concentration of CCh (50
nM) can enhance fEPSP slopes induced by single TS via
muscarinic M1 receptors, whereas excess acetylcholine concentration suppresses LTP.30,31 LTP induced by TS is dependent on the activation of N-methyl-D-aspartate (NMDA)
receptors32 and a rise in cellular Ca2þ concentration.33 The
appropriate concentration, 0.25 to 0.75 mM, of CCh alone
may induce LTP through muscarinic receptors but not
NMDA receptors.34 In this study, 50 nM CCh alone may not
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be able to induce LTP, suggesting subthreshold cholinergic
stimulation. Interestingly, subthreshold cholinergic stimulation with subthreshold TS can induce LTP, whereas CCh has
no effect on saturated LTP by repeated suprathreshold
tetani.34 Our data suggest that subthreshold cholinergic stimulation via muscarinic M1 receptors can enhance not only
subthreshold LTP induced by TS but also unsaturated LTP.
Soluble Ab fibril accumulation is thought to be an initial
change in synaptic dysfunction and memory loss in AD.35
Soluble Ab oligomers impair AMPA receptor trafficking on
synaptic membranes through CaMKII signaling.36 Synthetic
Ab dimers composed of the mutant Ab1-40, AbS26C, forms
stable proto-fibril-like assemblies including b-sheets. These
assemblies potently inhibit LTP in the mouse
hippocampus.17
Glutamatergic activation in the hippocampus is modulated by several neuronal networks including adrenergic and
cholinergic neurons. b2-adrenergic neurons influence LTP
through modulating AMPA receptors and N/L-type Ca2þ
channels.37 Enriched environments prevent the impairment
of hippocampal LTP through b2-adrenergic signals, when
LTP is incompletely suppressed by synthetic Ab oligomers.38 We previously reported that cholinergic stimulation
by CCh enhances LTP through muscarinic M1 receptors,
when LTP is induced by single TS.16 Muscarinic stimulation
contributes to the modulation of LTP in association with Ttype Ca2þ channels.37 In this study, we suggest that stimulation of muscarinic M1 receptors can, at least in part, prevent
LTP impairment by synthetic Ab oligomers. This result is
consistent with the effects of the cholinesterase inhibitor,
donepezil, for patients with AD in clinical settings.
The present study also demonstrated that HCNP overexpression could prevent LTP impairment induced by synthetic
Ab oligomers. Our previous study demonstrated that LTP in
HCNP-pp Tg mice was significantly enhanced relative to
that in WT mice and that this enhancement was mediated
by muscarinic M1, but not nicotinic, mechanisms. Therefore,
the improvement of Ab oligomer-induced LTP impairment
by HCNP overexpression may be derived from cholinergic
mechanisms. This finding might clinically suggest a new
kind of thinking for drug development.
As a limitation of this study, we could not directly determine the increase in acetylcholine synthesis in the hippocampus of HCNP-pp Tg mice to investigate our hypothesis
that acetylcholine modulates synaptic plasticity and its suppression by synthetic Ab oligomers through muscarinic M1
receptors. Additionally, HCNP-pp inhibits rapidly accelerated fibrosarcoma (Raf) and is therefore also referred to as
Raf kinase inhibitory protein. HCNP-pp is also an ATPbinding protein and a phosphatidylethanolamine-binding
protein. However, the present study could not demonstrate
the contribution of these functions to prevent synthetic
AbS26C oligomers from depressing LTP in HCNP-pp Tg
mice, while HCNP-pp may play an important role in cerebellar long-term synaptic depression by mediating protein
kinase C (PKC)-dependent mitogen-activated protein kinase
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(MAPK) activation.39 In the future, further experiments are
needed to elucidate the function of HCNP and/or HCNP-pp,
as well as cholinergic function, in a modulating effect on
synaptic plasticity in the hippocampus, including behavioral
effects.
In conclusion, we demonstrate that (1) preconditioning
TS can induce differential degrees of LTP depending on the
number of TS delivered and that the degree of LTP induction
possible is fixed to a maximum level and (2) HCNP/HCNPpp, as well as a cholinergic stimulant, can prevent the fEPSP
slope suppression induced by synthetic Ab oligomers in the
hippocampal LTP glutamatergic neuronal activity.
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